Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institute of Health, 9 Memorial Drive, Bethesda, MD 20892, USA.
Current drug targets (Impact Factor: 3.02). 08/2010; 11(8):1000-17. DOI: 10.2174/138945010791591395
Source: PubMed


New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway plays pivotal roles in regulating tumor angiogenesis. VEGF as a therapeutic target has been validated in various types of human cancers. Different agents including antibodies, aptamers, peptides, and small molecules have been extensively investigated to block VEGF and its pro-angiogenic functions. Some of these agents have been approved by FDA and some are currently in clinical trials. Combination therapies are also being pursued for better tumor control. By providing comprehensive real-time information, molecular imaging of VEGF pathway may accelerate the drug development process. Moreover, the imaging will be of great help for patient stratification and therapeutic effect monitoring, which will promote effective personalized molecular cancer therapy. This review summarizes the current status of tumor therapeutic agents targeting to VEGF and the applications of VEGF related molecular imaging.

Download full-text


Available from: Gang Niu, Sep 03, 2015
  • Source
    • "The National Institutes of Health (NIH) website provides a basic summary of anti-angiogenic drugs that were or are still currently under clinical investigations ( These include monoclonal antibodies targeting VEGF ligands or VEGFRs [14], soluble receptors that sequester ligands [15] and small molecule inhibitors that inhibit kinase activity [16]. Three drugs developed for their anti-angiogenic actions, bevacizumab (Avastin®), sunitinib malate (Sutent®, SU11248) and sorafenib (Nexavar®, BAY 43-9006), have been approved by the United States Food and Drug Administration for treatment of patients with specific types of cancer—all three inhibit VEGF signaling by blocking VEGF ligand or VEGFR [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-angiogenesis targeting VEGFR2 has been considered as an important strategy for cancer therapy. Tylophorine is known to possess anti-inflammatory and antitumor activity, but its roles in tumor angiogenesis, the key step involved in tumor growth and metastasis, and the involved molecular mechanism is still unknown. Therefore, we examined its anti-angiogenic effects and mechanisms in vitro and in vivo. We used tylophorine and analyzed its inhibitory effects on human umbilical vein endothelial cells (HUVEC) in vitro and Ehrlich ascites carcinoma (EAC) tumor in vivo. Tylophorine significantly inhibited a series of VEGF-induced angiogenesis processes including proliferation, migration, and tube formation of endothelial cells. Besides, it directly inhibited VEGFR2 tyrosine kinase activity and its downstream signaling pathways including Akt, Erk and ROS in endothelial cells. Using HUVECs we demonstrated that tylophorine inhibited VEGF-stimulated inflammatory responses including IL-6, IL-8, TNF-alpha, IFN-gamma, MMP-2 and NO secretion. Tylophorine significantly inhibited neovascularization in sponge implant angiogenesis assay and also inhibited tumor angiogenesis and tumor growth in vivo. Molecular docking simulation indicated that tylophorine could form hydrogen bonds and aromatic interactions within the ATP-binding region of the VEGFR2 kinase unit. Tylophorine exerts anti-angiogenesis effects via VEGFR2 signaling pathway thus, may be a viable drug candidate in anti-angiogenesis and anti-cancer therapies.
    Molecular Cancer 07/2013; 12(1):82. DOI:10.1186/1476-4598-12-82 · 4.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The author describes the KSR 1 system software and its role in bringing the benefits of programmability and scalability to the user. The system software consists of KSR OS, a UNIX compatible operating system, the preprocessors and compilers that comprise the language system, and the parallel programming tools that provide analysis and synthesis support to the parallel programmer
    Compcon Spring '93, Digest of Papers.; 03/1993
  • [Show abstract] [Hide abstract]
    ABSTRACT: Physiological angiogenesis occurs during embryogenesis, wound healing and reproductive functions in adults. Abnormal angiogenesis takes place in certain chronic diseases (diabetes, psoriasis, rheumatoid arthritis, etc.) and tumours. Genetic changes and local stresses including hypoxia, glucose deprivation and oxidative stress play a pivotal role in angiogenesis switch, which is necessary for tumour development and is rate-limiting for tumour progression. Angiogenesis is tightly regulated by pro- and anti-angiogenic growth factors with a series of complex and interrelated steps. Activated endothelial cells (ECs) migrate as a solid cord and, subsequently, form lumina; the sprout tips then anastomose to form vessel loops or networks. One of the final events is the laying down of a basement membrane and the structural support of pericytes. The molecular alterations that sustain angiogenesis represent novel targets for rationally designed anti-cancer treatment strategies. Inhibition of angiogenesis presents certain advantages on conventional therapies, such as the direct accessibility from the circulation, and the potential low rate of drug resistance related to the genetic stability of ECs. Certain anti-angiogenic compounds were found to have potent anticancer property in in vivo experimental studies. Nevertheless, in contrast to preclinical studies, the first generation of anti-angiogenic drugs tested in clinical trials have shown a moderate activity in advanced disease partly due to suboptimal schedules of therapy or biases in study design.
    Angiogenesis 02/2002; 5(4):237-56. DOI:10.1023/A:1024532022166 · 4.88 Impact Factor
Show more